AFT PHARMACEUTICALS LIMITED — Investor Relations & Filings

AFT Pharmaceuticals Limited focuses on the development, licensing, and distribution of a diverse range of healthcare products. The company specializes in therapeutic areas such as pain management, eye care, dermatology, and allergy relief. Its primary proprietary product is Maxigesic, a patented combination of paracetamol and ibuprofen designed for enhanced analgesic effect, which is licensed in numerous international markets. The company maintains a robust pipeline of research and development projects aimed at creating innovative delivery systems and formulations. AFT Pharmaceuticals manages a portfolio comprising both prescription and over-the-counter medicines. Its business strategy involves direct sales operations in specific regions alongside a global licensing model that extends its product reach to over 100 countries. The company prioritizes clinical evidence and intellectual property to support its commercial growth and product efficacy.